Patients best interests

The expansion of direct-to-consumer advertisements during the past five years has only served to reinforce this trend of putting patients into the role of informed purchasers of health care products.47 Critics argue that this can run counter to patients best interests. For example, physicians have noted a rapid increase in requests for specific drugs, including cases where patients ask for completely inappropriate treatments.48 A recent report to the pharmaceutical industry on ways to improve direct advertising thus recommends depth of content, accuracy, and objectivity as key to personalized health solutions and... 

Provision of such services must not jeopardise the counsellor s or the collaborating physician s clinical autonomy, who must at all times be bound to the ethical obligation to take independent medical decisions and exercise his or her medical profession in patients best interests. 

Definitive information about the clinical effectiveness of DHA is important both for the patients and their families and for the scientific community. Provision of an unproven or ineffective therapy may provide a false sense of security and retard the introduction of new approaches and thus be counter to the patients best interests. Furthermore, there still are unresolved disputes about the optimal modes of DHA therapy. Which DHA preparation is most effective Should arachidonic acid supplementation be provided along with DHA Although at this time the titration of the DHA dosage is based on total levels of this substance in plasma and red blood cells, it is possible that follow-up of the levels of this fatty acid in specific lipid moieties might be more informative. Would it be effective and safe to increase the plasma DHA levels to higher than normal Carefully designed clinical trials are required to answer these questions. 

Moving suitable patients into a DM service takes patience, sensitivity, and care. Patients cannot be treated en bloc, and any transfer should come as the result of individual negotiation between the doctor and the patient. The doctor will have to be convinced that what he/she is recommending is in the patients best interest. Anything short of outright support for the change on the part of the doctor will not do. They have to be convinced. 

Anonymous. Ramelteon application withdrawn. Ramelteon in insomnia withdrawal of marketing application in patients best interests. Prescrire Int 2009 18(101) 114. 

In the United Kingdom, two recent high profile cases, in which there was a difference of opinion as to what constituted best interests, have highlighted the difficulties in this area. The parents of two children, Charlotte Whyatt and Luke Winston-Jones (1), went to the high court to demand that, in the event of deterioration, their children would be resuscitated and receive advanced respiratory support in an intensive care unit (ICU). This has resulted in much debate, as in both cases the medical decisions were upheld and it was decided that mechanical ventilation and resuscitation was not in the patients best interests. 

The concept of integrating healthcare professionals expertise for the patient s best interest is not a new one for pharmacists. Speaking at a 1989 conference focusing on evolving pharmacy practice for the 21st century, Hepler and Strand reviewed the alarming extent of drug-related morbidity and mortality in the American healthcare system. They... 

See, Sellv. United States, 539 U,S, 166,213 (2003) [ [e]very State provides avenues through which, for example, a doctor or institution can seek appointment of a guardian with the power to make a decision authorizing medication - when in the best interests of a patient who lacks the mental competence to make such a decision ,]... 

For example, Schwetz says that sometimes it becomes evident early on that a trial is not working and researchers know they are not going to get enough meaningful information to make continuation worthwhile. In addition, if an unexpected change occurs in the health status of a participant, such as toxic effects or sudden kidney problems that may have developed, it would not be in the best interest of the patient to continue, and certainly not consistent with what the investigator is trying to study, he says. In any case, the circumstances must be described in the consent document. 

Selfishness Physicians have a duty to act in the best interests of their patients. Pharmaceutical companies have a duty not only to their shareholders, but also to the community at large. To fulfill their duty to the community, pharmaceutical companies must operate within the confines of socially acceptable behavior or risk loss of reputation, public boycotts, or legislative action. Socially unacceptable behavior by a company can ultimately lead to loss of business and become a failure in its duty to its shareholders. Both the physicians and the pharmaceutical companies or their employees must not compromise these public duties in order to gain financial or other material benefits for themselves, their families or their friends. 

Not covered in this book are ethical issues, which may be harder to solve than some technical problems. Considering ethical issues, it is useful to start by contemplating the Hippocratic Code the patient, after having agreed to be treated by a physician, trusts the physician to act in the patient s best interest no other ethical problem arises. This is an entirely different situation from one in which a physician-scientist s interest is the promotion of knowledge. 

As a pharmacist you are expected to take the steps that a reasonably competent pharmacist would take to ensure that a supply of medication is made in the best interests of the patient. The Royal Pharmaceutical Society of Great Britain (RPSGB) (2007) would expect these steps to include ... 

Although the patient s best interests are at the heart of any ethical discussion, it is important to consider the interests of all the major stakeholders, in this case the health care team looking after Mrs GG and the local health economy as well as Mrs GG herself. 

IV. A pharmacist acts with honesty and integrity in professional relationships. A pharmacist has a duty to tell the truth and to act with conviction of conscience. A pharmacist avoids discriminatory practices, behavior, or work conditions that impair professional judgment, and actions that compromise dedication to the best interests of patients. 

Ethically, the restriction of movement of a potentially infectious person is highly problematic. It violates the core of the ANA Code of Ethics, respect for the inherent dignity of individuals—the nurse s primary commitment to the patient (ANA, 2001). In the event of a public health emergency, a nurse may have a corresponding obligation to the community. The nurse should work to resolve the dilemma in such a way to ensure patient safety, guard the patient s best interests and preserve the professional integrity of the nurse (ANA, 2001, p. 10). 

Pharmacists then deliver the prescribed drugs to patients or to patients designees and provide counseling about proper drug use. Cooperation between pharmacists and prescribers is vital to patients best health interests and often results in positive refinements in the drug use process.The spirit of trust and commitment to high ethical and professional standards with regard to confidentiality of patient information is, of course, essential in the prescriber-pharmacist relationship. 

However, the policy that obtained was to send those who were not likely to recover quickly to the base [general] hospitals, though this was not always to the patient s best interests, for these larger hospitals were oftentimes centers of infection of one kind or another, especially of hospital gangrene [pyemia], which seldom attacked the wounded in the field. ... 

Compendial approaches are developed to protect the public and guide pharmaceutical manufacturers, prescribers, and dispensers. It is in the best interest of all stakeholders that quality pharmaceuticals be available for immediate patient use. In fact, it is imperative at all stages of drug distribution that the quality be maintained, both from the perspective of patient safety and from the standpoint of customer satisfaction and product liability. For these reasons, pharmacopeial standards throughout the world articulate accepted testing protocols and minimum quality standards to ensure that manufacturers have the tools they need to guarantee the quality of the available drug supply. 

Even a perfectly safe remedy (mainstream or unorthodox) can become unsafe when used incompetently. Medical competence can be defined as doing everything in the best interest of the patient according to the best available evidence. There are numerous circumstances, both in orthodox and complementary medicine, when competence is jeopardized ... 

The purpose of the trial must always be the improvement of therapeutic, diagnostic methods and/or medical knowledge to the best interest of patients. 

Pharmacists are faced with product efficacy, patient safety, liability, and reimbursement issues when medications are used for unlabeled indications. Lack of FDA approval for a specific use should not prevent a pharmacist from dispensing an available drug. Rather, drugs should be used in a manner consistent with good medical practice and in the patient s best interest. It is good pro-... 

The principles and methods of pharmacoeconomics provide the means to quantify the value of pharmacotherapy through balancing costs and outcomes. Providing quahty care with minimal resources is the future, and the future is here. By understanding the principles, methods, and application of pharmacoeconomics, health care professionals wih be prepared to make better, more-informed decisions regarding the use of pharmaceutical products and services, that is, decisions that ultimately represent the best interests of the patient, the health care system, and society. 

The Right to Emergency Care. The patient has a right to the best emergency care and cannot be transferred unless it is in the patient s best interests because of superior medical care. The patient must have access to all relevant information and if the patient does not agree to the transfer, he or she may not be transferred. ... 

Security services will be provided for applications to apply appropriate business rules for access control of records based on the identity, roles, and purposes (i.e., business functions), in addition to distributed security services for authentication, authorization, confidentiality, integrity and nonrepudiation, to protect the best interests of stakeholders. Later in this book we will discuss the notion of a stakeholder in healthcare. It suffices here to say that these are the people legitimately involved in healthcare such as the patient, physician, and emergency medical staff. In some definitions stakeholders are the only people who can access the patient record. There are usually a special provisionings for the emergency care staff to access the patient data without an explicit informed consent in the event that the patient is unconscious. 

Between 1987 and 1991, the FDA received Treatment IND petitions for 37 drugs, allowed distribution to patients in 23 of these cases, and approved 14 NDAs or PLAs/ELAs for drugs with Treatment IND status (98). The modest number of Treatment INDs is partially explained by the few drugs under development at any time for the treatment of serious or life-threatening diseases and the even smaller number meeting the criteria set forth in the regulations. Furthermore, even if a drug potentially qualifies for Treatment IND status, the sponsor may decide that participation is not in its best interest. 

It would make sense from a practical standpoint that manufacturers err on the side of caution rather than attempt to take extreme shortcuts in order to be the first to market. It is in everyone s best interest to see that all necessary precautions are taken to produce and market therapies that have the least risk and greatest rewards for aU concerned. Everyone has a major stake in this new frontier, and the manufacturers have to be extremely careful as to do the right things to ensure acceptance for marketability. Regulatory bodies have to ensure that all conceivable precautions are undertaken in order that a safe and reliable product comes to market. Patients want this increased competition so that they may access biosimilar therapies that may result in cost savings. These factors are intercoimected, and may produce a win-win scenario for aU parties. 

---